NNT to prevent one symptomatic VTE or VTE-related death and NNH to cause one major or fatal bleeding event for individual trials and overall pooled estimates.

The size of red bubbles is proportional to number of patients in the trial, and the size of the black bubble is proportional to accrued information size. The overall pooled estimates for NNH and NNT were calculated by conducting random effects meta-analyses for risk difference for primary efficacy and safety events. Safer implies higher NNH for causing one major or fatal bleeding event. Efficacious implies lower NNT to prevent one symptomatic VTE or VTE-related death. ADOPT, Apixaban Dosing to Optimize Protection from Thrombosis; APEX, Acute Medically Ill Venous Prevention with Extended Duration Betrixaban; EXCLAIM, Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization; MAGELLAN, Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin; MARINER, Medically Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk; NNH, number need to harm; NNT, number needed to treat; VTE, venous thromboembolism.